Fibrosis: Clinical Trials

311 trials for Fibrosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

311 completed. 311 Phase 2, 59 Phase 1, 34 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2311Completed 311
Phase 159Completed 59
Phase 334Completed 34

Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis

Trials (filtered) newest first · largest first

All 311 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
AZD2389 - Liver Fibrosis, Hepatic Cirrhosis
Phase 2CompletedAstraZeneca402024-12-062026-07-06
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Phase 2CompletedEndeavor Biomedicines, Inc.2132024-11-152026-11-17
Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems
Lemborexant, Placebo - Cirrhosis, Liver Cirrhosis
Phase 2CompletedUniversitas Indonesia822024-10-012026-03-18
Infusion of Allogeneic Stromal Mesenchymal Stem Cells From Wharton´s Jelly in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement to Treatment
Mesenchymal Stem Cells from Wharton´s jelly - Systemic Sclerosis Pulmonary, Pulmonary Hypertension
Phase 1 / Phase 2CompletedFundación Neumologica Colombiana12024-05-152026-04-21
A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia (OP-724-H201)
Foscenvivint - Liver Cirrhosis
Phase 2CompletedKiminori Kimura, MD52024-05-082026-05-01
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin - Liver Cirrhosis
Phase 2CompletedAstraZeneca732024-02-152026-01-20
Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.
K-808 (Dose A), K-808 (Dose B), Placebo - Primary Biliary Cholangitis
Phase 2CompletedKowa Research Institute, Inc.462024-02-072026-10-07
Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease
Dasatinib 100 MG + Quercetin (1000 MG), Placebo - NAFLD, NASH With Fibrosis
Phase 1 / Phase 2CompletedAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)302023-07-052026-04-15
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
INS018_055, Placebo - Idiopathic Pulmonary Fibrosis (IPF)
Phase 2CompletedInSilico Medicine Hong Kong Limited712023-06-192025-12-11
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic
Phase 2CompletedAtea Pharmaceuticals, Inc.2752023-05-302025-10-21
Intralesional Metformin Versus Triamcinolone for Keloid Treatment
Intralesional Metformin, Intralesional Triamcinolone Acetonide - Keloids
Phase 2CompletedAl-Azhar University302023-05-062026-11-06
A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction
golexanolone, Placebo - Primary Biliary Cholangitis (PBC)
Phase 1 / Phase 2CompletedUmecrine Cognition AB2072023-04-142026-10-16
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
AZD2693, Placebo - Nonalcoholic Steatohepatitis
Phase 2CompletedAstraZeneca2202023-03-152026-10-28
Study to Assess Efficacy and Safety of Dupilumab in the Treatment of Keloids
Dupilumab - Keloid
Phase 2CompletedBeth Israel Deaconess Medical Center202023-01-132026-09-18
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
IOA-289 - Metastatic Pancreatic Cancer
Phase 1 / Phase 2CompletediOnctura162022-10-102026-03-30
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
EP547, Placebo - Pruritus
Phase 2CompletedEscient Pharmaceuticals, Inc622022-10-062025-07-31
REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study
Sirolimus 0.5Mg Tab, 1st MRI scan, 1st Percutaneous or Endoscopic Ultrasound guided liver biopsy - Advanced Chronic Liver Disease
Phase 2CompletedNottingham University Hospitals NHS Trust412022-07-252024-10-01
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Cotadutide, Placebo - Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Phase 2CompletedAstraZeneca542022-07-142025-09-03
Safety, Tolerability and Efficacy of Nefopam Cream in Burn Patients
Nefopam, Placebo (Vehicle) - Burn; Multiple Body Regions, Max. Second Degree, Third-Degree Burn
Phase 2CompletedUniversity of Alberta502022-07-102026-07-24
A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar
AK3280 Cream, Placebo cream - Hypertrophic Scar
Phase 1 / Phase 2CompletedShanghai Ark Biopharmaceutical Co., Ltd.302022-07-082026-06-22

Showing 20 of 311. Sign in to see all of them.

Narrower conditions

Liver Cirrhosis (75)  ·  Cicatrix (45)  ·  Pulmonary Fibrosis (36)  ·  Liver Cirrhosis, Biliary (33)  ·  Non-alcoholic Fatty Liver Disease (26)  ·  Hepatitis C (21)  ·  Hypertension, Portal (18)  ·  Keloid (18)  ·  Idiopathic Pulmonary Fibrosis (17)  ·  Ascites (14)  ·  Hepatic Encephalopathy (13)  ·  Cicatrix, Hypertrophic (12)  ·  Fatty Liver (11)  ·  Liver Diseases (11)

Broader conditions

Pathological Conditions, Signs and Symptoms (311)  ·  Pathologic Processes (307)  ·  Digestive System Diseases (167)  ·  Liver Diseases (155)  ·  Liver Cirrhosis (36)  ·  Respiratory Tract Diseases (35)  ·  Skin and Connective Tissue Diseases (35)  ·  Bile Duct Diseases (34)  ·  Biliary Tract Diseases (33)  ·  Cholestasis, Intrahepatic (32)  ·  Infections (32)  ·  Lung Diseases (32)  ·  RNA Virus Infections (32)  ·  Virus Diseases (32)

Interventions

TGFB3 protein, human (14)  ·  pirfenidone (10)  ·  Ribavirin (6)  ·  Rituximab (6)  ·  3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (5)  ·  Saline Solution (5)  ·  Transforming Growth Factor beta3 (5)  ·  Albumins (4)  ·  Diet (4)  ·  Exercise (4)  ·  Sodium Chloride (4)  ·  Terlipressin (4)  ·  simtuzumab (4)  ·  Allopurinol (3)  ·  Botulinum Toxins, Type A (3)

Sponsors

Renovo (17)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (13)  ·  Gilead Sciences (10)  ·  Pfizer (6)  ·  Hospital Clinic of Barcelona (5)  ·  University of Alberta (5)  ·  AstraZeneca (4)  ·  Boehringer Ingelheim (4)  ·  Bristol-Myers Squibb (4)  ·  Conatus Pharmaceuticals Inc. (4)  ·  National Heart, Lung, and Blood Institute (NHLBI) (4)  ·  Novartis Pharmaceuticals (4)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Capstone Therapeutics (3)

Countries

United States (155)  ·  United Kingdom (53)  ·  Canada (45)  ·  Germany (41)  ·  Spain (40)  ·  Italy (34)  ·  France (33)  ·  Belgium (24)  ·  China (22)  ·  Australia (21)  ·  Japan (14)  ·  Argentina (13)  ·  Czechia (13)  ·  Netherlands (13)  ·  South Korea (11)

Top investigators

Jonathan Duncan (5)  ·  James Bush (3)  ·  David Hagerty, MD (2)  ·  Hossein Baharvand, PhD (2)  ·  Jaime Bosch, MD (2)  ·  James Bush, MBChB (2)

Results publications

PMID 19362676, PMID 28993537, PMID 33657443, PMID 38780109, PMID 39115183, PMID 10077078, PMID 11242330, PMID 11348456, PMID 12845617, PMID 15316341, PMID 16442954, PMID 16544259, PMID 16651948, PMID 16734808, PMID 16901024, PMID 16987047, PMID 17147494, PMID 17206944, PMID 17356110, PMID 17721093, PMID 17903050, PMID 18068515, PMID 18184077, PMID 18346996, PMID 18508290, PMID 18534768, PMID 18555763, PMID 18580208, PMID 18669816, PMID 18843115, PMID 18945255, PMID 19215252, PMID 19289689, PMID 19341651, PMID 19357910, PMID 19594300, PMID 19797971, PMID 19802513, PMID 19877169, PMID 19898214, PMID 20007927, PMID 20009818, PMID 20012639, PMID 20440184, PMID 20506355, PMID 20541828, PMID 20677940, PMID 20684729, PMID 20739168, PMID 20953964

NIH funding

2016 (8), 2004 (2), 2005 (2), 2009 (2), 2015 (2), 2017 (2), 2019 (2), 2023 (2), K01HL096434 (1), N01CN00035 (1), N01CN00042 (1), P30CA015083 (1), P30CA060553 (1), P30CA124435 (1), P50HL067665 (1)